CO6140060A2 - Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 - Google Patents
Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5Info
- Publication number
- CO6140060A2 CO6140060A2 CO08116342A CO08116342A CO6140060A2 CO 6140060 A2 CO6140060 A2 CO 6140060A2 CO 08116342 A CO08116342 A CO 08116342A CO 08116342 A CO08116342 A CO 08116342A CO 6140060 A2 CO6140060 A2 CO 6140060A2
- Authority
- CO
- Colombia
- Prior art keywords
- hydrogen
- alkyl
- compound according
- fluoro
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Un compuesto de fórmula (I)dondeR1 es metil, halógeno o ciano;R2 es hidrógeno o fluoro;R3 es hidrógeno, fluoro o alquil C1-C3;R4 es alquil C1-C3 o ciclopropil; Y es un enlace, CR8, O, S, SO, SO2, o NR9;X esy Z es donde R5 es hidrógeno, alquil C1-C3, haloalquil C1-C3, alcoxi C1-C3; haloalcoxi C1-C3; o halógeno; R6 es hidrógeno, alquil C1-C3, haloalquil C1-C3, alcoxi C1-C3; haloalcoxi C1-C3; o halógeno; R7 es hidrógeno, fluoro o alquil C1-C3;R8 es hidrógeno, fluoro o alquil C1-C3; R9 es hidrógeno o alquil C1-C3; así como sales, hidratos, isoformas, tautómeros y/o enantiómeros del mismo farmacéuticamente aceptables. 2.- Un compuesto de acuerdo con la reivindicación 1, donde R1 es halógeno o ciano. 3.- Un compuesto de acuerdo con la reivindicación 2, donde R1 es cloro. 4.- Un compuesto de acuerdo con la reivindicación 2, donde R1 es fluoro. 5.- Un compuesto de acuerdo con la reivindicación 2, donde R1 es metil. 6.- Un compuesto de acuerdo con la reivindicación 2, donde R1 es ciano. 7.- Un compuesto de acuerdo con cualquiera de las reivindicaciones 1-6, donde R2 es hidrógeno. 8.- Un compuesto de acuerdo con cualquiera de las reivindicaciones 1-7, donde R3 es hidrógeno o fluoro.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79765906P | 2006-05-05 | 2006-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6140060A2 true CO6140060A2 (es) | 2010-03-19 |
Family
ID=38668440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO08116342A CO6140060A2 (es) | 2006-05-05 | 2008-10-30 | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 |
Country Status (19)
Country | Link |
---|---|
US (1) | US7678796B2 (es) |
EP (1) | EP2027120A2 (es) |
JP (1) | JP2009536209A (es) |
KR (1) | KR20090009952A (es) |
CN (1) | CN101506202A (es) |
AR (1) | AR060651A1 (es) |
AU (1) | AU2007248288A1 (es) |
BR (1) | BRPI0710979A2 (es) |
CA (1) | CA2650114A1 (es) |
CL (1) | CL2007001174A1 (es) |
CO (1) | CO6140060A2 (es) |
EC (1) | ECSP088864A (es) |
IL (1) | IL194814A0 (es) |
MX (1) | MX2008013835A (es) |
NO (1) | NO20084850L (es) |
RU (1) | RU2008141509A (es) |
TW (1) | TW200811157A (es) |
UY (1) | UY30304A1 (es) |
WO (1) | WO2007130820A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005214378A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
GEP20125425B (en) * | 2006-10-18 | 2012-03-26 | Pfizer Prod Inc | Biaryl ether urea compounds |
CA2884347C (en) | 2007-08-13 | 2019-10-15 | Monsanto Technology Llc | Methods for the control of plant parasitic nematodes comprising application of oxadiazole compounds to plants, seeds or soil |
KR20100090777A (ko) | 2007-10-19 | 2010-08-17 | 아스트라제네카 아베 | 대사성 글루타메이트 수용체 (mglur)의 조절제로서의 테트라졸 유도체 |
WO2009054792A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Aminopyridine derivatives as modulators of mglur5 |
WO2009054791A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5 |
AU2008317544A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amino 1,2,4-triazole derivatives as modulators of mGluR5 |
WO2009054789A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5 |
WO2009054787A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5 |
WO2009054790A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
TW200922586A (en) * | 2007-10-26 | 2009-06-01 | Astrazeneca Ab | Thiophene 1,2,4-triazole derivatives as modulators of mGluR5 |
WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
CN102285914B (zh) * | 2010-06-18 | 2013-12-25 | 上海药明康德新药开发有限公司 | 2-(1-甲基-6-羰基-1,6-二氢-吡啶)-乙酸的合成方法 |
UA114468C2 (uk) * | 2010-09-02 | 2017-06-26 | Монсанто Текнолоджи Ллс | Композиції і способи контролю нематод як шкідників сільського господарства |
UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
GB201215033D0 (en) * | 2012-08-23 | 2012-10-10 | Novartis Ag | Diazepinone derivatives |
DK2900659T3 (en) * | 2012-09-27 | 2016-10-03 | Hoffmann La Roche | ARYLETHYNYL DERIVATIVES |
AR095330A1 (es) | 2013-03-15 | 2015-10-07 | Monsanto Technology Llc | Azoles n-,c-disustituidos y composiciones y métodos para controlar plagas de nematodos |
EP2857387A1 (en) | 2013-10-07 | 2015-04-08 | Boehringer Ingelheim International Gmbh | Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid |
US11512067B2 (en) * | 2017-09-14 | 2022-11-29 | Daiichi Sankyo Company, Limited | Compound having cyclic structure |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014370A2 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
US7074809B2 (en) * | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
KR20050033070A (ko) | 2002-08-09 | 2005-04-08 | 아스트라제네카 에이비이 | 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸 |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
RU2006129324A (ru) | 2004-02-18 | 2008-04-10 | Астразенека Аб (Se) | Конденсированные гетероциклические соединения и их применение в качестве антагонистов метаботропных глутаматных рецепторов |
KR20070027504A (ko) | 2004-02-18 | 2007-03-09 | 아스트라제네카 아베 | 테트라졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도 |
AU2005214378A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
GB0514296D0 (en) | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
-
2007
- 2007-04-24 TW TW096114401A patent/TW200811157A/zh unknown
- 2007-04-25 AU AU2007248288A patent/AU2007248288A1/en not_active Abandoned
- 2007-04-25 WO PCT/US2007/067367 patent/WO2007130820A2/en active Application Filing
- 2007-04-25 US US11/790,417 patent/US7678796B2/en not_active Expired - Fee Related
- 2007-04-25 CL CL2007001174A patent/CL2007001174A1/es unknown
- 2007-04-25 UY UY30304A patent/UY30304A1/es not_active Application Discontinuation
- 2007-04-25 BR BRPI0710979-2A patent/BRPI0710979A2/pt not_active IP Right Cessation
- 2007-04-25 MX MX2008013835A patent/MX2008013835A/es not_active Application Discontinuation
- 2007-04-25 KR KR1020087029720A patent/KR20090009952A/ko not_active Application Discontinuation
- 2007-04-25 RU RU2008141509/04A patent/RU2008141509A/ru not_active Application Discontinuation
- 2007-04-25 CA CA002650114A patent/CA2650114A1/en not_active Abandoned
- 2007-04-25 EP EP07761248A patent/EP2027120A2/en not_active Withdrawn
- 2007-04-25 JP JP2009509953A patent/JP2009536209A/ja active Pending
- 2007-04-25 CN CNA2007800252941A patent/CN101506202A/zh active Pending
- 2007-04-25 AR ARP070101781A patent/AR060651A1/es unknown
-
2008
- 2008-10-22 IL IL194814A patent/IL194814A0/en unknown
- 2008-10-30 CO CO08116342A patent/CO6140060A2/es unknown
- 2008-11-05 EC EC2008008864A patent/ECSP088864A/es unknown
- 2008-11-18 NO NO20084850A patent/NO20084850L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200811157A (en) | 2008-03-01 |
WO2007130820A3 (en) | 2008-03-13 |
AR060651A1 (es) | 2008-07-02 |
ECSP088864A (es) | 2008-12-30 |
AU2007248288A1 (en) | 2007-11-15 |
US20070259862A1 (en) | 2007-11-08 |
CL2007001174A1 (es) | 2008-01-18 |
US7678796B2 (en) | 2010-03-16 |
NO20084850L (no) | 2008-12-02 |
KR20090009952A (ko) | 2009-01-23 |
MX2008013835A (es) | 2008-11-10 |
WO2007130820A2 (en) | 2007-11-15 |
RU2008141509A (ru) | 2010-06-20 |
JP2009536209A (ja) | 2009-10-08 |
IL194814A0 (en) | 2009-08-03 |
EP2027120A2 (en) | 2009-02-25 |
BRPI0710979A2 (pt) | 2011-05-31 |
UY30304A1 (es) | 2007-11-30 |
CA2650114A1 (en) | 2007-11-15 |
CN101506202A (zh) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
CO6220935A2 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
ES2564782T3 (es) | Compuestos derivados de 1-aril-5-alquil pirazol, procedimientos de fabricación y procedimientos de utilización de los mismos | |
AR060813A1 (es) | Moduladores de mglur5 iii | |
AR050266A1 (es) | Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa | |
DK2091948T3 (da) | Nye inhibitorer af glutaminylcyclase | |
SV2009003233A (es) | Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide | |
PE20142099A1 (es) | Derivados de sulfonamida | |
AR060812A1 (es) | Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn | |
DE602005016775D1 (de) | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion | |
NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
PE20120101A1 (es) | Pirazoles fungicidas | |
TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
CY1112914T1 (el) | Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης | |
NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
EA201170096A1 (ru) | Замещенные производные пиримидона | |
RS53246B (en) | DERIVATI IMIDAZOLA KAO INHIBITORI KAZEIN KINAZE | |
AR060810A1 (es) | Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn | |
RS53133B (en) | PIRAZOL DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
PE20140968A1 (es) | Derivados de benzamida sustituida | |
CO5700763A2 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra | |
AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
AR060652A1 (es) | Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii) |